Amiodarone is a potent antidysrhythmic agent that can cause potentially life-threatening
pulmonary fibrosis. Accumulating evidence has demonstrated that myofibroblast …

Amiodarone is a high effectiveness anti-arrhythmia agent which is able to induce pulmonary
fibrosis. Many studies have shown that the epithelial-mesenchymal transition (EMT) was a …

Amiodarone (AM) is an antidysrhythmic agent with a propensity to cause pulmonary toxicity,
including potentially fatal fibrosis. In the present study, the potential roles of c-Jun and …

Amiodarone (AD) is a highly efficient antiarrhythmic drug with potentially serious side effects.
Severe pulmonary toxicity is reported in patients receiving AD even at low doses and may …

Background Fibroblast to myofibroblast transition is believed to contribute to airway
remodelling in lung diseases such as asthma and chronic obstructive pulmonary disease …

The long‐term side effect of the antiarrhythmic drug, amiodarone (AMIO), such as lung
toxicity, remains a critical clinical issue. The previous knowledge denotes diverse …

Amiodarone (AM) is an effective anti-arrhythmic drug. We investigated the role of mast cells
and macrophages on AM induced pulmonary fibrosis and the action of atorvastatin on this …

Background: Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal fibrotic lung
disease with an unknown aetiology. Persistent myofibroblast differentiation is a prominent …

The therapeutic role of mesenchymal stem cells (MSCs) in cases of amiodarone (AD)
induced pulmonary fibrosis (PF) has not been well studied. Also, the period required by …

Amiodarone (AMD), an antiarrhythmic drug, is used cautiously due to its lung toxicity that is
characterized by alveolar inflammation followed by fatal fibrosis. AMD induces lung …